January 1 – June 30, 2007
• Net sales for the period amounted to SEK 33.5 M (28.6)
• Profit after tax was SEK 10.7 M (8.3)
• Earnings per share after tax amounted to SEK 0.94 (0.72)
• Operating profit amounted to SEK 14.3 M (11.3)
• Cash flow from operating activities amounted to SEK 19,8 M (19.2)
• New collaboration agreement with Varian Medical Systems was signed in May
After the end of the reporting period
• New collaboration agreement with TomoTherapy was signed in August
• Application to the FDA for 510(k) approval for the sale of the Compass product platform in the US was filed in August
CEO comments
“We are highly pleased to announce today a new collaboration agreement with TomoTherapy, which becomes our fifth partner,” says Johan Löf, President and CEO of RaySearch.
“We have also posted a favorable financial development during the period and we are involved in a number of discussions regarding new license agreements so I view the future with great optimism.”
Stockholm, August 29, 2007
RaySearch Laboratories AB
Johan Löf, President and CEO
Press releases
